132 related articles for article (PubMed ID: 33468811)
1. [Selection of Operative Procedure for Breast Cancer in Carriers of BRCA VUS in Japan].
Kakimoto M; Asai D; Akamine K; Kobayashi R; Yamazaki N; Morimoto Y; Kubo K; Yamada N; Kobayashi A; Ogata K; Hasegawa K
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2092-2094. PubMed ID: 33468811
[TBL] [Abstract][Full Text] [Related]
2. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
Valachis A; Nearchou AD; Lind P
Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer treatment in mutation carriers: surgical treatment.
Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
[TBL] [Abstract][Full Text] [Related]
4. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
Vallard A; Magné N; Guy JB; Espenel S; Rancoule C; Diao P; Deutsch E; Rivera S; Chargari C
Br J Radiol; 2019 May; 92(1097):20170657. PubMed ID: 30810334
[TBL] [Abstract][Full Text] [Related]
5. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
6. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
Davey MG; Davey CM; Ryan ÉJ; Lowery AJ; Kerin MJ
Breast; 2021 Apr; 56():26-34. PubMed ID: 33582622
[TBL] [Abstract][Full Text] [Related]
7. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
Wang C; Lin Y; Zhu H; Zhou Y; Mao F; Huang X; Zhou X; Cao X; Sun Q
Breast Cancer; 2022 Mar; 29(2):314-323. PubMed ID: 34766244
[TBL] [Abstract][Full Text] [Related]
8. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients.
Guo Y; Wan Q; Ouyang T; Li J; Wang T; Fan Z; Xie Y
Breast; 2022 Oct; 65():55-60. PubMed ID: 35820297
[TBL] [Abstract][Full Text] [Related]
9. Breast Conserving Surgery for BRCA Mutation Carriers-A Systematic Review.
Co M; Liu T; Leung J; Li CH; Tse T; Wong M; Kwong A
Clin Breast Cancer; 2020 Jun; 20(3):e244-e250. PubMed ID: 32144082
[TBL] [Abstract][Full Text] [Related]
10. Management of hereditary breast and ovarian cancer.
Yamauchi H; Takei J
Int J Clin Oncol; 2018 Feb; 23(1):45-51. PubMed ID: 29185095
[TBL] [Abstract][Full Text] [Related]
11. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
12. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
13. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh N; Webster RD; Gutierrez Barrera AM; Lin H; Kuerer HM; Litton JK; Bedrosian I; Arun BK
Cancer Med; 2018 Jun; 7(6):2718-2726. PubMed ID: 29733510
[TBL] [Abstract][Full Text] [Related]
14. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
[TBL] [Abstract][Full Text] [Related]
15. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan.
Yamauchi H; Okawa M; Yokoyama S; Nakagawa C; Yoshida R; Suzuki K; Nakamura S; Arai M
Breast Cancer Res Treat; 2018 Dec; 172(3):679-687. PubMed ID: 30203341
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer.
Evron E; Ben-David AM; Goldberg H; Fried G; Kaufman B; Catane R; Pfeffer MR; Geffen DB; Chernobelsky P; Karni T; Abdah-Bortnyak R; Rosengarten O; Matceyevsky D; Inbar M; Kuten A; Corn BW
Ann Oncol; 2019 Mar; 30(3):412-417. PubMed ID: 30475942
[TBL] [Abstract][Full Text] [Related]
17. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
[TBL] [Abstract][Full Text] [Related]
18. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
[TBL] [Abstract][Full Text] [Related]
19. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
[TBL] [Abstract][Full Text] [Related]
20. Determinants of Breast-Conserving Therapy in the Asian Population: A Systematic Review.
Galeano Machuca MP; Cheng SC; Jou TH; Cheng CT
World J Surg; 2021 Mar; 45(3):799-807. PubMed ID: 33051701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]